Cobimetinib and trametinib inhibit platelet MEK but do not cause platelet dysfunction
Sign Up to like & getrecommendations! Published in 2019 at "Platelets"
DOI: 10.1080/09537104.2018.1514107
Abstract: Abstract The MEK inhibitors cobimetinib and trametinib are used in combination with BRAF inhibitors to treat metastatic melanoma but increase rates of hemorrhage relative to BRAF inhibitors alone. Platelets express several members of the MAPK… read more here.
Keywords: mek inhibitors; platelet dysfunction; mek; platelet ... See more keywords